Welcome to our dedicated page for Mind Medicine SEC filings (Ticker: MNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates for brain health disorders, and its filings offer detailed information on clinical progress, financing transactions and corporate matters.
Through Forms 8‑K, MindMed reports material events such as underwritten public offerings of common shares under its shelf registration statement on Form S‑3, entry into underwriting agreements, and the intended use of proceeds to fund research and development, working capital and general corporate purposes. Other 8‑K filings describe the release of quarterly financial results, updated corporate presentations, and announcements related to clinical and scientific milestones, including publication of MM120 trial data in generalized anxiety disorder.
MindMed’s filings also identify its jurisdiction of incorporation in British Columbia, Canada, its listing of common shares on The Nasdaq Stock Market LLC under the symbol MNMD, and its status as an emerging growth company. Investors can use this page to review prospectus supplements, opinions and exhibits referenced in 8‑K filings, as well as periodic reports such as Forms 10‑K and 10‑Q accessed via EDGAR.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, such as the terms of public offerings, changes in cash and investments, and updates on the development of MM120 and MM402. Real-time updates from EDGAR, along with structured access to Forms 10‑K, 10‑Q and 4, help users quickly locate information on MindMed’s financial condition, capital structure and insider-related disclosures.
Definium Therapeutics director Roger Adsett received a grant of stock options on 01/29/2026. The award covers options to buy 50,000 common shares at an exercise price of $17.24 per share, all held directly.
The options vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in 24 equal monthly installments, contingent on Mr. Adsett’s continued service to the company.
Definium Therapeutics, Inc. reported a change to its board of directors. On January 28, 2026, the board expanded from six to seven members and appointed Roger Adsett as a director effective January 29, 2026, with a term running until the 2026 annual general meeting, or until a successor is chosen or he departs earlier.
Adsett was not assigned to any board committees at this time. Under the company’s non-employee director compensation policy, he will receive an annual cash retainer of $40,000, paid quarterly on a pro-rata basis. He also received an option to purchase 50,000 common shares, vesting one-third on the first anniversary of the grant date and the remainder in equal monthly installments thereafter, subject to continued board service.
The option grant was issued under the company’s 2025 Equity Incentive Plan. The filing notes there are no special arrangements leading to his appointment and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., reported estimated preliminary cash, cash equivalents and investments of about $412 million as of December 31, 2025, shared in a corporate presentation posted online. This figure is unaudited, may change, and has not been reviewed or examined by KPMG LLP.
The company has officially changed its corporate name to Definium Therapeutics, Inc., with board approval and updated British Columbia corporate records. The rebranding is described as aligning with its next phase as a psychiatric drug development leader. Common shares will keep the same CUSIP and begin trading on the Nasdaq under the new ticker “DFTX” starting January 13, 2026, with no action required from shareholders.
Mind Medicine (MindMed) Inc. (MNMD) reported Q3 results and liquidity updates. The company recorded a net loss of $67.3 million for the quarter, driven by operating expenses of $45.7 million (research and development $31.0 million; general and administrative $14.7 million) and a $22.5 million non-cash loss from the change in fair value of 2022 USD Financing Warrants. Basic and diluted net loss per share were $0.78.
As of September 30, 2025, cash and cash equivalents were $19.96 million and short-term investments were $189.11 million. Total assets were $236.9 million against total liabilities of $106.3 million, resulting in shareholders’ equity of $130.6 million. Common shares outstanding were 76,774,057 as of quarter-end; 98,509,279 were outstanding as of October 31, 2025.
Subsequent to quarter-end, on October 31, 2025, the company closed an underwritten public offering for gross proceeds of $258.9 million (net $242.8 million) to fund product development and general purposes. Earlier in 2025, MindMed amended its K2 HealthVentures credit facility, funded $42.0 million in a first tranche, and saw $1.0 million converted into 249,377 common shares.
Mind Medicine (MindMed) Inc. (MNMD) furnished an update via an 8-K announcing it issued a press release with financial results for its second quarter ended September 30, 2025, including information about a conference call to discuss the results and recent corporate highlights.
The company also posted an updated corporate presentation on its website. The press release is provided as Exhibit 99.1, and the presentation as Exhibit 99.2.
Mind Medicine (MindMed) Inc. (MNMD) announced an underwritten public offering of 18,375,000 common shares at $12.25 per share. Underwriters were granted a 30‑day option to buy up to 2,756,250 additional shares at the same price, which was exercised in full on October 30, 2025. Gross proceeds are expected to be approximately $258.9 million, with estimated net proceeds of $242.8 million after discounts and expenses. The offering is expected to close on October 31, 2025.
The company plans to use net proceeds to fund research and development of its product candidates, as well as for working capital and general corporate purposes. A portion may be used for potential investments or acquisitions, though there are no current agreements. Directors and executive officers agreed to a 90‑day lock‑up. The offering was made under MindMed’s effective shelf registration statement on Form S‑3 with a base prospectus and prospectus supplement.
Mind Medicine (MindMed) Inc. is offering 18,375,000 common shares at $12.25 per share in a primary follow‑on under its S‑3 shelf. The deal implies a gross offering size of $225,093,750, with underwriting discounts of $13,505,625 and estimated net proceeds of approximately $211.1 million after expenses. The company granted underwriters a 30‑day option for up to 2,756,250 additional shares.
MindMed expects to use proceeds for research and development of its pipeline, including MM120 for generalized anxiety disorder and major depressive disorder and MM402 for autism spectrum disorder, plus working capital and general corporate purposes. Shares outstanding will be 94,178,251 after the offering (or 96,934,501 if the option is fully exercised). As of September 30, 2025, cash, cash equivalents and investments were approximately $209.1 million.
The shares trade on Nasdaq as MNMD. Delivery is expected on or about October 31, 2025.
Mind Medicine (MindMed) Inc. disclosed preliminary liquidity. The company reported estimated unaudited cash, cash equivalents and investments of approximately $209.1 million as of September 30, 2025. This figure was included in a prospectus supplement and an updated corporate presentation posted on October 29, 2025.
Management emphasized that the estimate is preliminary and subject to completion, and that the company’s independent auditor, KPMG LLP, has not audited, reviewed, or compiled this information. The company noted that adjustments may be required once customary procedures are completed.
MindMed also filed the corporate presentation as Exhibit 99.1, making the materials available for investors seeking additional context on its financial position.
Mind Medicine (MindMed) Inc. filed a preliminary prospectus supplement for a primary offering of common shares and pre‑funded warrants, with joint bookrunners Jefferies, Leerink Partners and Evercore ISI. The company has also granted the underwriters a 30‑day option to purchase additional common shares. Net proceeds will go to research and development of product candidates and to working capital and general corporate purposes.
Pre‑funded warrants will be immediately exercisable until fully exercised and include ownership caps of 4.99% or 9.99% at the holder’s election, adjustable up to 19.99% with notice. MNMD trades on Nasdaq; the last reported price was $12.87 per share on October 28, 2025. Shares outstanding were 75,803,251 as of June 30, 2025; this is a baseline figure, not the amount being offered.
The company reported approximately $209.1 million in cash, cash equivalents and investments as of September 30, 2025. MindMed is advancing MM120 into Phase 3 for generalized anxiety disorder and major depressive disorder, and planning a Phase 2a study of MM402 in autism spectrum disorder.
Robert Barrow, Chief Executive Officer and director of Mind Medicine (MindMed) Inc. (MNMD), reported a sale of 25,797 common shares on 09/25/2025 at a price of $9.77 per share. The filing states the shares were sold to satisfy withholding tax obligations arising from the settlement of vested restricted stock units, executed under a Rule 10b5-1 plan adopted on June 15, 2022.
Following the transaction, Mr. Barrow beneficially owned 804,268 shares. The Form 4 was signed by an attorney-in-fact on 09/26/2025 and was filed as a single reporting person filing. The disclosure lists this as a routine sell-to-cover related to RSU vesting rather than an open-market discretionary sale.